Keymed Biosciences Announces 2025 Annual Results and Business Updates

Keymed’s NewCo Partner Ouro Medicines Enters into Acquisition Agreement with Gilead Sciences to Accelerate Global Development of Potential Best-in-Class TCE CM336/OM336

Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine

Keymed Biosciences Announces Interim Results for First Half of 2024

Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM